GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Policy Acquisition Expense

GLPG (Galapagos NV) Policy Acquisition Expense


View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Galapagos NV Business Description

Industry
Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.